GlassScriptPhysician profile
Nigel Thomas Goodchild
NPI 1235116682
$628.35
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $375 · 2020: $190 · 2022: $63.18.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $142.57 | 2019-2020 | |
| Janssen Biotech, INC. | $91.99 | 2019-2020 | |
| Astellas Pharma US INC | $74.23 | 2019-2022 | |
| Lilly USA, LLC | $52.72 | 2019 | |
| Genzyme Corporation | $51.86 | 2019-2020 | |
| Tesaro, INC. | $44.42 | 2019 | |
| Incyte Corporation | $34.87 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $32.43 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $18.58 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.93 | 2020 | |
| Agios Pharmaceuticals, INC. | $16.90 | 2019 | |
| Puma Biotechnology, INC. | $13.71 | 2020 | |
| Seagen INC. | $12.51 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.33 | 2019 | |
| Celgene Corporation | $11.30 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nigel Goodchild listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.